Corporate VCs join Hookipa's €20m series B
This article was originally published in Scrip
Two corporate investors have joined Hookipa Biotech of Austria's €20 million ($27.5 million) series B financing. Existing investors Sofinnova Partners and Forbion Capital Partners led the financing, with three new investors, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners joining the round.
You may also be interested in...
Private Company Edition: Flagship ends 2017 with its biggest life science fund yet totaling $618m. Also, December sees a year-end surge in VC deals, including a $100m Series B round for Allakos.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.